COVID-19 vaccine clinical trial report in NEJM, co-authored by Robert Frenck, MD, sets new record for most-shared study involving experts at Cincinnati Children’s.

Mentioned in more than 400 news articles and shared through more than 15,000 tweets reaching more than 26 million followers, the clinical trial report that led to the emergency use approval of the first vaccine in the United States to protect against COVID-19 ranks as the most widely-read research ever co-authored by an investigator from Cincinnati Children’s.

The paper, “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,” published Dec. 10, 2020, in The New England Journal of Medicine, reflects the combined contributions of  a multinational clinical trial group that included researchers from the U.S., Brazil, United Kingdom, Germany, Argentina, Turkey, and South Africa. Among the co-authors, Robert Frenck, MD, who has played a prominent role in tracking and speaking about how the vaccine works in adolescents.

Reflecting the urgency of the most devastating pandemic in a century, the paper ranks among the 50 most-shared research articles of all 30 million-plus studies to be tracked by Altmetric.

Also among the most-shared research in December, 2020, from Cincinnati Children’s:

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

The New England Journal of Medicine

Cincinnati Children’s co-author: Robert Frenck, MD

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Nature Medicine

Cincinnati Children’s co-authors: David I. Bernstein, MD, MA, and Monica McNeal, BS

Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia

Annals of Internal Medicine

Cincinnati Children’s co-author: Adrienne Hammill, MD